Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Nivolumab Treatment for Cancers in the HIV-infected Population.

Chang E, Sabichi AL, Kramer JR, Hartman C, Royse KE, White DL, Patel NR, Richardson P, Yellapragada SV, Garcia JM, Chiao EY.

J Immunother. 2018 Jul 16. doi: 10.1097/CJI.0000000000000240. [Epub ahead of print]

PMID:
30020193
2.

Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder.

Chang E, Sabichi AL, Sada YH.

J Immunother. 2017 Apr;40(3):114-116. doi: 10.1097/CJI.0000000000000161. Review.

PMID:
28234667
3.

Reply to J. Cabezas et al.

Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS.

J Clin Oncol. 2016 Jan 20;34(3):290-1. doi: 10.1200/JCO.2015.64.3064. Epub 2015 Dec 7. No abstract available.

PMID:
26644541
4.

Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.

Hwang JP, Somerfield MR, Alston-Johnson DE, Cryer DR, Feld JJ, Kramer BS, Sabichi AL, Wong SL, Artz AS.

J Clin Oncol. 2015 Jul 1;33(19):2212-20. doi: 10.1200/JCO.2015.61.3745. Epub 2015 May 11.

5.

HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer.

Zhu H, Berkova Z, Mathur R, Sehgal L, Khashab T, Tao RH, Ao X, Feng L, Sabichi AL, Blechacz B, Rashid A, Samaniego F.

Mol Cancer Res. 2015 May;13(5):809-18. doi: 10.1158/1541-7786.MCR-14-0241. Epub 2015 Feb 12.

6.

Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex.

Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, Sabichi AL, Ao X, Maeng H, Samaniego F.

Blood. 2013 Jun 6;121(23):4729-39. doi: 10.1182/blood-2012-12-471094. Epub 2013 Apr 18.

7.

Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.

El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, Lippman S, Esmaeli B.

Arch Ophthalmol. 2012 Dec;130(12):1608-11. doi: 10.1001/archophthalmol.2012.2515. No abstract available.

PMID:
23229707
8.

Benefits and harms of CT screening for lung cancer: a systematic review.

Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC.

JAMA. 2012 Jun 13;307(22):2418-29. doi: 10.1001/jama.2012.5521. Review. Erratum in: JAMA. 2013 Jun 5;309(21):2212. JAMA. 2012 Oct 3;308(13):1324.

9.

A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.

Sabichi AL, Lee JJ, Grossman HB, Liu S, Richmond E, Czerniak BA, De la Cerda J, Eagle C, Viner JL, Palmer JL, Lerner SP.

Cancer Prev Res (Phila). 2011 Oct;4(10):1580-9. doi: 10.1158/1940-6207.CAPR-11-0036. Epub 2011 Aug 31.

10.

System level changes in gene expression in maturing bladder mucosa.

Dozmorov M, Stone R 2nd, Clifford JL, Sabichi AL, Engles CD, Hauser PJ, Culkin DJ, Hurst RE.

J Urol. 2011 May;185(5):1952-8. doi: 10.1016/j.juro.2010.12.101. Epub 2011 Mar 21.

11.

Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

Chiong E, Lee IL, Dadbin A, Sabichi AL, Harris L, Urbauer D, McConkey DJ, Dickstein RJ, Cheng T, Grossman HB.

Clin Cancer Res. 2011 May 1;17(9):2863-73. doi: 10.1158/1078-0432.CCR-09-3202. Epub 2011 Mar 17.

12.

American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.

Artz AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, Zon RT, Wong SL.

J Clin Oncol. 2010 Jul 1;28(19):3199-202. doi: 10.1200/JCO.2010.30.0673. Epub 2010 Jun 1.

PMID:
20516452
13.

Identification of genes correlated with early-stage bladder cancer progression.

Stone R 2nd, Sabichi AL, Gill J, Lee IL, Adegboyega P, Dai MS, Loganantharaj R, Trutschl M, Cvek U, Clifford JL.

Cancer Prev Res (Phila). 2010 Jun;3(6):776-86. doi: 10.1158/1940-6207.CAPR-09-0189. Epub 2010 May 25.

14.

Mortality in the randomized, controlled lung intergroup trial of isotretinoin.

Lee JJ, Feng L, Reshef DS, Sabichi AL, Williams B, Rinsurongkawong W, Wistuba II, Lotan R, Lippman SM.

Cancer Prev Res (Phila). 2010 Jun;3(6):738-44. doi: 10.1158/1940-6207.CAPR-09-0124. Epub 2010 May 25.

15.

Three synchronous HPV-associated squamous cell carcinomas of Waldeyer's ring: case report and comparison with Slaughter's model of field cancerization.

McGovern SL, Williams MD, Weber RS, Sabichi A, Chambers MS, Martin JW, Chao KS.

Head Neck. 2010 Aug;32(8):1118-24. doi: 10.1002/hed.21171.

PMID:
19572386
16.

The use of short tandem repeat profiling to characterize human bladder cancer cell lines.

Chiong E, Dadbin A, Harris LD, Sabichi AL, Grossman HB.

J Urol. 2009 Jun;181(6):2737-48. doi: 10.1016/j.juro.2009.01.108. Epub 2009 Apr 17.

17.

High-dose fenretinide in oral leukoplakia.

William WN Jr, Lee JJ, Lippman SM, Martin JW, Chakravarti N, Tran HT, Sabichi AL, Kim ES, Feng L, Lotan R, Papadimitrakopoulou VA.

Cancer Prev Res (Phila). 2009 Jan;2(1):22-6. doi: 10.1158/1940-6207.CAPR-08-0100.

18.

Forced COX-2 expression induces PGE(2) and invasion in immortalized urothelial cells.

Gee J, Lee IL, Grossman HB, Sabichi AL.

Urol Oncol. 2008 Nov-Dec;26(6):641-5. doi: 10.1016/j.urolonc.2007.05.015. Epub 2008 Jan 8.

PMID:
18367112
19.

Clinical model of cost of bladder cancer in the elderly.

Cooksley CD, Avritscher EB, Grossman HB, Sabichi AL, Dinney CP, Pettaway C, Elting LS.

Urology. 2008 Mar;71(3):519-25. doi: 10.1016/j.urology.2007.10.056.

PMID:
18342201
20.

Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray.

Harris LD, De La Cerda J, Tuziak T, Rosen D, Xiao L, Shen Y, Sabichi AL, Czerniak B, Grossman HB.

Mol Carcinog. 2008 Sep;47(9):678-85. doi: 10.1002/mc.20420.

21.

Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.

Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP 3rd, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM.

Clin Cancer Res. 2008 Jan 1;14(1):224-9. doi: 10.1158/1078-0432.CCR-07-0733.

22.

Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma.

Brewster AM, Lee JJ, Clayman GL, Clifford JL, Reyes MJ, Zhou X, Sabichi AL, Strom SS, Collins R, Meyers CA, Lippman SM.

J Clin Oncol. 2007 May 20;25(15):1974-8.

PMID:
17513803
23.

Clinical model of lifetime cost of treating bladder cancer and associated complications.

Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS.

Urology. 2006 Sep;68(3):549-53. Epub 2006 Sep 18.

PMID:
16979735
24.

Comparative outcomes of bladder cancer.

Cárdenas-Turanzas M, Cooksley C, Pettaway CA, Sabichi A, Grossman HB, Elting L.

Obstet Gynecol. 2006 Jul;108(1):169-75.

PMID:
16816072
25.

15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor gamma.

Subbarayan V, Krieg P, Hsi LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG.

Oncogene. 2006 Sep 28;25(44):6015-25. Epub 2006 May 8.

PMID:
16682954
26.

Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.

Sabichi AL, Lee JJ, Taylor RJ, Thompson IM, Miles BJ, Tangen CM, Minasian LM, Pisters LL, Caton JR, Basler JW, Lerner SP, Menter DG, Marshall JR, Crawford ED, Lippman SM.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2178-84.

27.
28.

Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer.

Gee J, Lee IL, Jendiroba D, Fischer SM, Grossman HB, Sabichi AL.

Oncol Rep. 2006 Feb;15(2):471-7.

PMID:
16391871
29.

RARbeta1': primed to fight retinoid resistance in lung carcinogenesis.

Sabichi AL, Xu X, Lippman SM.

J Natl Cancer Inst. 2005 Nov 16;97(22):1632-3. No abstract available.

PMID:
16288110
30.

Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer.

Kim J, Sun P, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM.

Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1697-702.

31.

Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products.

Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG.

Cancer Res. 2005 Jul 15;65(14):6189-98.

32.

Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia.

Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG.

Neoplasia. 2005 Mar;7(3):280-93.

33.

Transitional cell hyperplasia and carcinomas in urinary bladders of transgenic mice with keratin 5 promoter-driven cyclooxygenase-2 overexpression.

Klein RD, Van Pelt CS, Sabichi AL, Dela Cerda J, Fischer SM, Fürstenberger G, Müller-Decker K.

Cancer Res. 2005 Mar 1;65(5):1808-13.

34.

Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells.

Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG.

Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1710-6.

35.

Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells.

Sabichi AL, Subbarayan V, Llansa N, Lippman SM, Menter DG.

Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1704-9.

36.

Focus on bladder cancer.

Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B.

Cancer Cell. 2004 Aug;6(2):111-6. Review. No abstract available.

37.

COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer.

Sabichi AL, Lippman SM.

Semin Oncol. 2004 Apr;31(2 Suppl 7):36-44. Review.

PMID:
15179622
38.

Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.

Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG.

J Biol Chem. 2004 Apr 30;279(18):19191-200. Epub 2004 Feb 24.

39.

Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.

Sabichi AL, Xu H, Fischer S, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, Clifford JL.

Clin Cancer Res. 2003 Oct 1;9(12):4606-13.

40.

The risk of second primary tumors after resection of stage I nonsmall cell lung cancer.

Rice D, Kim HW, Sabichi A, Lippman S, Lee JJ, Williams B, Vaporciyan A, Smythe WR, Swisher S, Walsh G, Putnam JB Jr, Hong WK, Roth J.

Ann Thorac Surg. 2003 Oct;76(4):1001-7; discussion 1007-8.

PMID:
14529975
41.

Frontiers in cancer prevention research.

Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM.

Cancer Res. 2003 Sep 15;63(18):5649-55. No abstract available.

42.

Cytokeratin 20, AN43, PGDH, and COX-2 expression in transitional and squamous cell carcinoma of the bladder.

Gee JR, Montoya RG, Khaled HM, Sabichi AL, Grossman HB.

Urol Oncol. 2003 Jul-Aug;21(4):266-70.

PMID:
12954496
43.

Centrosomal abnormality is common in and a potential biomarker for bladder cancer.

Jiang F, Caraway NP, Sabichi AL, Zhang HZ, Ruitrok A, Grossman HB, Gu J, Lerner SP, Lippman S, Katz RL.

Int J Cancer. 2003 Sep 20;106(5):661-5.

44.

Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.

Sabichi AL, Modiano MR, Lee JJ, Peng YM, Xu MJ, Villar H, Dalton WS, Lippman SM.

Clin Cancer Res. 2003 Jul;9(7):2400-5.

45.

COX-2 inhibitors and other NSAIDs in bladder and prostate cancer.

Sabichi AL, Lippman SM.

Prog Exp Tumor Res. 2003;37:163-78. Review. No abstract available.

PMID:
12795054
46.

Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth.

Kinoshita I, Leaner V, Katabami M, Manzano RG, Dent P, Sabichi A, Birrer MJ.

Oncogene. 2003 May 8;22(18):2710-22.

PMID:
12743595
47.

Chemoprevention of superficial bladder cancer.

Gee J, Sabichi AL, Grossman HB.

Crit Rev Oncol Hematol. 2002 Sep;43(3):277-86. Review.

PMID:
12270783
48.

Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer.

Clifford JL, Sabichi AL, Zou C, Yang X, Steele VE, Kelloff GJ, Lotan R, Lippman SM.

Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):391-5.

49.

Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells.

Subbarayan V, Sabichi AL, Llansa N, Lippman SM, Menter DG.

Cancer Res. 2001 Mar 15;61(6):2720-6.

50.

Selenium effects on prostate cell growth.

Menter DG, Sabichi AL, Lippman SM.

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1171-82.

Supplemental Content

Loading ...
Support Center